Last reviewed · How we verify

Irinotecan Liposomal Injection [Onivyde]

Seoul National University Hospital · Phase 3 active Small molecule

Irinotecan Liposomal Injection [Onivyde] is a Topoisomerase I inhibitor Small molecule drug developed by Seoul National University Hospital. It is currently in Phase 3 development for Metastatic pancreatic cancer (in combination with 5-fluorouracil and leucovorin), Metastatic colorectal cancer. Also known as: nal-IRI, Nal-IRI.

Irinotecan liposomal injection is a topoisomerase I inhibitor encapsulated in liposomes that prevents DNA unwinding and causes cancer cell death.

Irinotecan liposomal injection is a topoisomerase I inhibitor encapsulated in liposomes that prevents DNA unwinding and causes cancer cell death. Used for Metastatic pancreatic cancer (in combination with 5-fluorouracil and leucovorin), Metastatic colorectal cancer.

At a glance

Generic nameIrinotecan Liposomal Injection [Onivyde]
Also known asnal-IRI, Nal-IRI
SponsorSeoul National University Hospital
Drug classTopoisomerase I inhibitor
TargetTopoisomerase I
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Irinotecan inhibits topoisomerase I, an enzyme required for DNA replication and transcription. The liposomal formulation improves drug delivery to tumors and reduces systemic toxicity compared to conventional irinotecan. This allows for better accumulation in cancer cells while minimizing exposure to healthy tissues.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Irinotecan Liposomal Injection [Onivyde]

What is Irinotecan Liposomal Injection [Onivyde]?

Irinotecan Liposomal Injection [Onivyde] is a Topoisomerase I inhibitor drug developed by Seoul National University Hospital, indicated for Metastatic pancreatic cancer (in combination with 5-fluorouracil and leucovorin), Metastatic colorectal cancer.

How does Irinotecan Liposomal Injection [Onivyde] work?

Irinotecan liposomal injection is a topoisomerase I inhibitor encapsulated in liposomes that prevents DNA unwinding and causes cancer cell death.

What is Irinotecan Liposomal Injection [Onivyde] used for?

Irinotecan Liposomal Injection [Onivyde] is indicated for Metastatic pancreatic cancer (in combination with 5-fluorouracil and leucovorin), Metastatic colorectal cancer.

Who makes Irinotecan Liposomal Injection [Onivyde]?

Irinotecan Liposomal Injection [Onivyde] is developed by Seoul National University Hospital (see full Seoul National University Hospital pipeline at /company/seoul-national-university-hospital).

Is Irinotecan Liposomal Injection [Onivyde] also known as anything else?

Irinotecan Liposomal Injection [Onivyde] is also known as nal-IRI, Nal-IRI.

What drug class is Irinotecan Liposomal Injection [Onivyde] in?

Irinotecan Liposomal Injection [Onivyde] belongs to the Topoisomerase I inhibitor class. See all Topoisomerase I inhibitor drugs at /class/topoisomerase-i-inhibitor.

What development phase is Irinotecan Liposomal Injection [Onivyde] in?

Irinotecan Liposomal Injection [Onivyde] is in Phase 3.

What are the side effects of Irinotecan Liposomal Injection [Onivyde]?

Common side effects of Irinotecan Liposomal Injection [Onivyde] include Neutropenia, Diarrhea, Nausea and vomiting, Fatigue, Anemia, Thrombocytopenia.

What does Irinotecan Liposomal Injection [Onivyde] target?

Irinotecan Liposomal Injection [Onivyde] targets Topoisomerase I and is a Topoisomerase I inhibitor.

Related